Basic studies on the lipiodolization of miriplatin in combination with CDDP

Platinum release and initial hepatic toxicity of a formulation containing both miriplatin (MPT) and cisplatin (CDDP), prepared to improve the weak initial effect of MPT-Lipiodol (LPD) suspension, were evaluated. No difference in platinum release from CDDP was found between CDDP-LPD and MPT·CDDP-LPD,...

Full description

Saved in:
Bibliographic Details
Published inGan to kagaku ryoho Vol. 41; no. 12; p. 2104
Main Authors Kishimoto, Shuichi, Adachi, Shingo, Masui, Aya, Suzuki, Ryosuke, Beppu, Toru, Fukushima, Shoji
Format Journal Article
LanguageJapanese
Published Japan 01.11.2014
Subjects
Animals
Cisplatin - administration & dosage
Cisplatin - chemistry
Cisplatin - toxicity
Female
Infusions, Intravenous
Lipids - chemistry
Liver - drug effects
Liver - physiology
Organoplatinum Compounds - administration & dosage
Organoplatinum Compounds - chemistry
Organoplatinum Compounds - toxicity
Rats, Sprague-Dawley
Online AccessGet more information

Cover

More Information
Summary:Platinum release and initial hepatic toxicity of a formulation containing both miriplatin (MPT) and cisplatin (CDDP), prepared to improve the weak initial effect of MPT-Lipiodol (LPD) suspension, were evaluated. No difference in platinum release from CDDP was found between CDDP-LPD and MPT·CDDP-LPD, which suggested that platinum release was not affected by the viscosity of MPT-LPD. On the day following administration into rat portal vein, drugs suspended in LPD increased liver function values, and these values returned to the previous levels 3 days after administration. Both the CDDP-LPD and MPT· CDDP-LPD groups showed higher liver function values than the MPT-LPD group, and there was little difference in liver function values between the CDDP-LPD and MPT·CDDP-LPD groups. Thus, MPT·CDDP-LPD retains the characteristics of MPTLPD and CDDP-LPD without reducing the effects of either drug or enhancing their side effects.
ISSN:0385-0684